Savara (NASDAQ:SVRA) Trading 5.6% Higher - Time to Buy?

Savara Inc (NASDAQ:SVRA - Get Free Report) shares shot up 5.6% on Thursday . The stock traded as high as $3.20 and last traded at $3.19. 138,171 shares changed hands during trading, a decline of 89% from the average session volume of 1,266,494 shares. The stock had previously closed at $3.02.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SVRA shares. HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Evercore ISI reaffirmed an "in-line" rating and set a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.17.

Savara Stock Up 7.0 %

The company's fifty day simple moving average is $3.49 and its 200 day simple moving average is $4.00. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $554.33 million, a PE ratio of -7.51 and a beta of 0.92.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). Analysts anticipate that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Joseph S. Mccracken bought 20,000 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. The trade was a 10.48 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now directly owns 1,536,379 shares of the company's stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On Savara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. increased its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock worth $32,874,000 after buying an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock worth $20,879,000 after purchasing an additional 3,443,541 shares during the last quarter. Farallon Capital Management LLC grew its position in Savara by 90.5% in the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company's stock worth $18,377,000 after purchasing an additional 2,165,701 shares during the period. First Light Asset Management LLC purchased a new stake in Savara during the 2nd quarter valued at $8,069,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Savara by 22.9% during the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company's stock valued at $36,566,000 after buying an additional 1,608,522 shares during the period. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.